Clinical Trial Update: Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a dendritic cell vaccine targeting defined mutated neoantigens in autologous cancer patients with melanoma or gastrointestinal cancers;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Melanoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Gastrointestinal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-12-13